XIU Xia,Ray Lin,Colin Chu,et al.Dosimetric and clinical comparison between MammoSite and interstitial HDR brachytherapy in treatment of early stage breast cancer after conserving surgery \[J].Chinese Journal of Radiological Medicine and Protection,2007,27(2):145-148 |
Dosimetric and clinical comparison between MammoSite and interstitial HDR brachytherapy in treatment of early stage breast cancer after conserving surgery \ |
Received:December 04, 2006 |
DOI: |
KeyWords:Early stage breast cancer MammoSite Interstitial Brachtherapy |
FundProject: |
|
Hits: 3015 |
Download times: 2008 |
Abstract:: |
Objective To comparatively study dosimetric evaluation, side effects in early and late stage, and cosmetic outcome between MammoSite and interstitial using high-dose-rate (HDR) brachytherapy accelerated partial breast irradiation (APBI) in early stage breast cancer patient after conserving surgery. Methods From January 2004 to December 2004, 10 breast cancer cases were treated with HDR 192Ir APBI after Lumpectomy surgery, 6 cases with interstitial brachytherapy, 4 cases with MammoSite. Sources were placed during the operation in all patients, distance from cavity to skin >5-7 mm in interstitial brachytherapy group, one case is 6.5 mm, 3 cases >10 mm in MammoSite group. Treatment Target area is 20 mm away from cavity in interstitial brachytherapy group with DHI 0.77, 10 mm away from Balloon margin in MammoSite with DHI 0.73. Results Follow up 12-24 months while median follow-up was 18 months for the whole group (100%). During the treatment, grade Ⅲ acute reactions were not seen in both group, grade Ⅰ or Ⅱ were seen including: erythema, edema, tenderness and infection. More late toxicity reaction including skin fibrosis, breast tenderness and fat necrosis were observed in interstitial brachytherapy group than that of MammoSite group. Cosmetic outcome evaluation were excellent in 12 months 100% (patient) and 83% (doctor) in interstitial brachytherapy, 100% in MammoSite group, respectively, none recurrence. Conclusions Interstitial brachytherapy shows more uniformity in dose distribution as well as larger treatment volume, while MammoSite tends to be stable in repeatability and easy in use. Both groups show excellent cosmetic results, with same acute and late reactions. |
HTML View Full Text View/Add Comment Download reader |
Close |
|
|
|